{
  "abstract": "Background\n\nMET amplification, although detected in only 2%-5% of intrahepatic cholangiocarcinomas (ICC), represents an actionable oncogenic driver. Treatment options after failure of first-line immunochemotherapy remain limited, and clinical data on vebreltinib, a novel highly selective MET inhibitor, in this molecular subset are scarce.Case presentation\n\nA 61-year-old woman with metastatic ICC harboring high-level MET amplification (tissue gene copy number, 26.79) experienced disease progression on first-line durvalumab plus gemcitabine/cisplatin, second-line liposomal irinotecan/fluorouracil plus lenvatinib and durvalumab, radiotherapy, and transarterial chemoembolization. Following a brief period of vebreltinib (200 mg twice daily) plus durvalumab that was interrupted by grade 4 myelosuppression, the patient continued on vebreltinib monotherapy after hematologic recovery. Restaging computed tomography demonstrated a partial response (PR), with carbohydrate antigen 19-9 normalizing (a 99.2% reduction). This response lasted over 6 months until eventual disease progression.Conclusion\n\nTo our knowledge, this is the first report of vebreltinib monotherapy inducing a deep and durable partial response in heavily pretreated, MET-amplified ICC, with the response lasting over 6 months despite eventual disease progression. This case underscores the critical value of comprehensive molecular profiling after first-line treatment failure to identify actionable drivers such as MET amplification.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine, Nanjing 210029, China.",
    "The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China.",
    "Jiangsu Collaborative Innovation Center of TCM Cancer Prevention and Treatment, Nanjing 210023, China.",
    "Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing 210032, China.",
    "Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China."
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Yingying Hang"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Lu Bai"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Hsiquan Hsu"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Ying Chen"
    },
    {
      "affs": [
        3
      ],
      "name": "Fufeng Wang"
    },
    {
      "affs": [
        3
      ],
      "name": "Wuyan Xu"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Xia Zhen"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Zihao Wang"
    },
    {
      "affs": [
        4
      ],
      "name": "Yuan Li"
    },
    {
      "affs": [
        0,
        1,
        2
      ],
      "name": "Jun Qian",
      "orcid": "0009-0007-5111-4429"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6my0d2v3t94mh.bib",
  "cited_by": 0,
  "doi": "10.1093/oncolo/oyag409",
  "fulltext_url": "https://europepmc.org/articles/PMC13685772",
  "id": "6my0d2v3t94mh",
  "issns": [
    "1083-7159",
    "1549-490X"
  ],
  "landing_url": "https://europepmc.org/article/MED/42870395",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2746|Cholangiocarcinoma and Gallbladder Cancer Studies"
    ]
  ],
  "openalex": "W7221830176",
  "pdf_url": "https://europepmc.org/articles/PMC13685772?pdf=render",
  "pmcid": "PMC13685772",
  "pmid": "42870395",
  "published": "2026-10-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/6my0d2v3t94mh.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:00Z",
      "native_id": "MED:42870395",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42870395"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2746|Cholangiocarcinoma and Gallbladder Cancer Studies",
      "subfield": "surgery"
    }
  ],
  "title": "Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report.",
  "title_text": "Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:00Z",
  "url": "https://research.draconitic.com/paper/6my0d2v3t94mh",
  "venue": "The oncologist",
  "versions": []
}